La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.

Identifieur interne : 001311 ( PubMed/Corpus ); précédent : 001310; suivant : 001312

Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.

Auteurs : R. Bordet ; S. Ridray ; J C Schwartz ; P. Sokoloff

Source :

RBID : pubmed:10886351

English descriptors

Abstract

Induction of dopamine D3 receptor gene expression in 6-hydroxydopamine-lesioned rats by repeated administration of levodopa had been suggested to be responsible for behavioural sensitization developing in these animals. Using double in situ hybridization techniques, we show that D3 receptor mRNA induction after repeated administration of levodopa took place mainly in dynorphin/substance P-expressing neurons of the direct striatonigral pathway. In agreement, induction of D3 receptor binding sites was evidenced, using 7-[3H]hydroxy-N,N-di-propyl-2-aminotetralin ([3H]7-OH-DPAT), in substantia nigra pars reticulata, the projection area of the direct nigrostriatonigral pathway. Changes in D3 receptor binding and behavioural sensitization during intermittent administration of levodopa paralleled changes in prodynorphin/preprotachykinin rather than preproenkephalin/prodynorphin and preproenkephalin/preprotachykinin mRNA ratios. Behavioural sensitization, induction of D3 receptor binding and changes in prodynorphin/preprotachykinin ratio were all prevented together when levodopa was continuously delivered or intermittently delivered in combination with R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4, 5-tetrahydro-1H-3-benzazepine (SCH 23390), a selective D1 receptor antagonist. Our results indicate that functional changes of the direct striatal output pathway, possibly through an interaction between D1 and D3 receptors at the level of terminals in the substantia nigra pars reticulata, are important for the development of behavioural sensitization.

PubMed: 10886351

Links to Exploration step

pubmed:10886351

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.</title>
<author>
<name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R" last="Bordet">R. Bordet</name>
<affiliation>
<nlm:affiliation>Unité de Neurobiologie et Pharmacologie Moléculaire (INSERM U 109), Centre Paul Broca, 2ter rue d'Alésia, 75014, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Ridray, S" sort="Ridray, S" uniqKey="Ridray S" first="S" last="Ridray">S. Ridray</name>
</author>
<author>
<name sortKey="Schwartz, J C" sort="Schwartz, J C" uniqKey="Schwartz J" first="J C" last="Schwartz">J C Schwartz</name>
</author>
<author>
<name sortKey="Sokoloff, P" sort="Sokoloff, P" uniqKey="Sokoloff P" first="P" last="Sokoloff">P. Sokoloff</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:10886351</idno>
<idno type="pmid">10886351</idno>
<idno type="wicri:Area/PubMed/Corpus">001311</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001311</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.</title>
<author>
<name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R" last="Bordet">R. Bordet</name>
<affiliation>
<nlm:affiliation>Unité de Neurobiologie et Pharmacologie Moléculaire (INSERM U 109), Centre Paul Broca, 2ter rue d'Alésia, 75014, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Ridray, S" sort="Ridray, S" uniqKey="Ridray S" first="S" last="Ridray">S. Ridray</name>
</author>
<author>
<name sortKey="Schwartz, J C" sort="Schwartz, J C" uniqKey="Schwartz J" first="J C" last="Schwartz">J C Schwartz</name>
</author>
<author>
<name sortKey="Sokoloff, P" sort="Sokoloff, P" uniqKey="Sokoloff P" first="P" last="Sokoloff">P. Sokoloff</name>
</author>
</analytic>
<series>
<title level="j">The European journal of neuroscience</title>
<idno type="ISSN">0953-816X</idno>
<imprint>
<date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Benzazepines (metabolism)</term>
<term>Benzazepines (pharmacology)</term>
<term>Binding, Competitive (physiology)</term>
<term>Corpus Striatum (cytology)</term>
<term>Denervation</term>
<term>Dizocilpine Maleate (pharmacology)</term>
<term>Dopamine Agonists (metabolism)</term>
<term>Dopamine Agonists (pharmacology)</term>
<term>Dopamine Antagonists (metabolism)</term>
<term>Dopamine Antagonists (pharmacology)</term>
<term>Enkephalins (genetics)</term>
<term>Excitatory Amino Acid Antagonists (pharmacology)</term>
<term>Gene Expression (physiology)</term>
<term>Levodopa (pharmacology)</term>
<term>Male</term>
<term>Neural Pathways</term>
<term>Neurons (chemistry)</term>
<term>Neurons (physiology)</term>
<term>Opioid Peptides (metabolism)</term>
<term>Oxidopamine</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (drug therapy)</term>
<term>Parkinson Disease, Secondary (pathology)</term>
<term>Protein Precursors (genetics)</term>
<term>RNA, Messenger (analysis)</term>
<term>Rats</term>
<term>Rats, Wistar</term>
<term>Receptors, Dopamine D2 (analysis)</term>
<term>Receptors, Dopamine D2 (genetics)</term>
<term>Receptors, Dopamine D3</term>
<term>Substantia Nigra (cytology)</term>
<term>Sympatholytics</term>
<term>Tachykinins (genetics)</term>
<term>Tetrahydronaphthalenes (metabolism)</term>
<term>Tetrahydronaphthalenes (pharmacology)</term>
<term>Tritium</term>
<term>Ventral Tegmental Area (cytology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en">
<term>RNA, Messenger</term>
<term>Receptors, Dopamine D2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Enkephalins</term>
<term>Protein Precursors</term>
<term>Receptors, Dopamine D2</term>
<term>Tachykinins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Benzazepines</term>
<term>Dopamine Agonists</term>
<term>Dopamine Antagonists</term>
<term>Opioid Peptides</term>
<term>Tetrahydronaphthalenes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Benzazepines</term>
<term>Dizocilpine Maleate</term>
<term>Dopamine Agonists</term>
<term>Dopamine Antagonists</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Levodopa</term>
<term>Tetrahydronaphthalenes</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en">
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en">
<term>Neurons</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en">
<term>Corpus Striatum</term>
<term>Substantia Nigra</term>
<term>Ventral Tegmental Area</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Binding, Competitive</term>
<term>Gene Expression</term>
<term>Neurons</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Denervation</term>
<term>Male</term>
<term>Neural Pathways</term>
<term>Oxidopamine</term>
<term>Rats</term>
<term>Rats, Wistar</term>
<term>Receptors, Dopamine D3</term>
<term>Sympatholytics</term>
<term>Tritium</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Induction of dopamine D3 receptor gene expression in 6-hydroxydopamine-lesioned rats by repeated administration of levodopa had been suggested to be responsible for behavioural sensitization developing in these animals. Using double in situ hybridization techniques, we show that D3 receptor mRNA induction after repeated administration of levodopa took place mainly in dynorphin/substance P-expressing neurons of the direct striatonigral pathway. In agreement, induction of D3 receptor binding sites was evidenced, using 7-[3H]hydroxy-N,N-di-propyl-2-aminotetralin ([3H]7-OH-DPAT), in substantia nigra pars reticulata, the projection area of the direct nigrostriatonigral pathway. Changes in D3 receptor binding and behavioural sensitization during intermittent administration of levodopa paralleled changes in prodynorphin/preprotachykinin rather than preproenkephalin/prodynorphin and preproenkephalin/preprotachykinin mRNA ratios. Behavioural sensitization, induction of D3 receptor binding and changes in prodynorphin/preprotachykinin ratio were all prevented together when levodopa was continuously delivered or intermittently delivered in combination with R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4, 5-tetrahydro-1H-3-benzazepine (SCH 23390), a selective D1 receptor antagonist. Our results indicate that functional changes of the direct striatal output pathway, possibly through an interaction between D1 and D3 receptors at the level of terminals in the substantia nigra pars reticulata, are important for the development of behavioural sensitization.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">10886351</PMID>
<DateCreated>
<Year>2000</Year>
<Month>08</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>2000</Year>
<Month>08</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2016</Year>
<Month>11</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0953-816X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>12</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2000</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>The European journal of neuroscience</Title>
<ISOAbbreviation>Eur. J. Neurosci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.</ArticleTitle>
<Pagination>
<MedlinePgn>2117-23</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Induction of dopamine D3 receptor gene expression in 6-hydroxydopamine-lesioned rats by repeated administration of levodopa had been suggested to be responsible for behavioural sensitization developing in these animals. Using double in situ hybridization techniques, we show that D3 receptor mRNA induction after repeated administration of levodopa took place mainly in dynorphin/substance P-expressing neurons of the direct striatonigral pathway. In agreement, induction of D3 receptor binding sites was evidenced, using 7-[3H]hydroxy-N,N-di-propyl-2-aminotetralin ([3H]7-OH-DPAT), in substantia nigra pars reticulata, the projection area of the direct nigrostriatonigral pathway. Changes in D3 receptor binding and behavioural sensitization during intermittent administration of levodopa paralleled changes in prodynorphin/preprotachykinin rather than preproenkephalin/prodynorphin and preproenkephalin/preprotachykinin mRNA ratios. Behavioural sensitization, induction of D3 receptor binding and changes in prodynorphin/preprotachykinin ratio were all prevented together when levodopa was continuously delivered or intermittently delivered in combination with R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4, 5-tetrahydro-1H-3-benzazepine (SCH 23390), a selective D1 receptor antagonist. Our results indicate that functional changes of the direct striatal output pathway, possibly through an interaction between D1 and D3 receptors at the level of terminals in the substantia nigra pars reticulata, are important for the development of behavioural sensitization.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bordet</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Unité de Neurobiologie et Pharmacologie Moléculaire (INSERM U 109), Centre Paul Broca, 2ter rue d'Alésia, 75014, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ridray</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schwartz</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sokoloff</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Eur J Neurosci</MedlineTA>
<NlmUniqueID>8918110</NlmUniqueID>
<ISSNLinking>0953-816X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C493595">Drd3 protein, rat</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004745">Enkephalins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018847">Opioid Peptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013565">Sympatholytics</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015320">Tachykinins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C044206">preprotachykinin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>10028-17-8</RegistryNumber>
<NameOfSubstance UI="D014316">Tritium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6LR8C1B66Q</RegistryNumber>
<NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8HW4YBZ748</RegistryNumber>
<NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>93443-35-7</RegistryNumber>
<NameOfSubstance UI="C033660">preproenkephalin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>RR7D75YDF4</RegistryNumber>
<NameOfSubstance UI="C031349">7-hydroxy-2-N,N-dipropylaminotetralin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001552" MajorTopicYN="N">Benzazepines</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003714" MajorTopicYN="N">Denervation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016291" MajorTopicYN="N">Dizocilpine Maleate</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004745" MajorTopicYN="N">Enkephalins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018847" MajorTopicYN="N">Opioid Peptides</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D050637" MajorTopicYN="N">Receptors, Dopamine D3</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013565" MajorTopicYN="N">Sympatholytics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015320" MajorTopicYN="N">Tachykinins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013764" MajorTopicYN="N">Tetrahydronaphthalenes</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017557" MajorTopicYN="N">Ventral Tegmental Area</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2000</Year>
<Month>7</Month>
<Day>11</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2000</Year>
<Month>8</Month>
<Day>19</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2000</Year>
<Month>7</Month>
<Day>11</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">10886351</ArticleId>
<ArticleId IdType="pii">ejn089</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001311 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001311 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:10886351
   |texte=   Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:10886351" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024